Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06561321 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma

StatusActive, Not Recruiting
PhasePhase 2
Started2024-10-30
View on ClinicalTrials.gov ↗

Amendment history

2026-06-18
Study Status, Contacts/Locations v7
Trial status changed: Recruiting → Active, Not Recruiting
Study sitesdetails revised at 1 of 1 site
2026-03-02
Study Status v6
Primary completion date2026-02-01→2027-12-31
Completion date2026-11-01→2027-12-31
2026-01-23
Study Status, Contacts/Locations v5
Study sitescontacts updated at 1 of 1 site
2026-01-22
Study Status, Sponsor/Collaborators v4
Collaborators1 entry, revised
DermavantOrganon Sciences,and Inc.Co
2024-12-19
Study Status v3
Completion date2026-02-01→2026-11-01
Show 2 earlier versions
2024-11-25
Study Status v2
Start dateestimated 2024-10-26→confirmed 2024-10-30
2024-09-13
Study Status v1
Start date2024-08-26→2024-10-26
2024-08-15
Original filing
The purpose of this study is to assess adults with palmoplantar keratoderma (thickening skin layer on palms and soles) who are treated with the study drug, tapinarof. This is a naturally occuring compound used for the treatment of psoriasis. This study is being done to find out how well and safe this drug is for stopping or treating keratoderma. This study aims to investigate the positive impacts of daily topical Tapinarof use in the improvement of Keratoderma. Clinical efficacy and safety profile of prescribing Tapinarof for this condition will be evaluated.
Trial Details
NCT Number NCT06561321
Lead Sponsor Indiana University
Collaborators: Organon and Co
Conditions Palmoplantar Keratoderma
Enrollment 6 participants
Start Date 2024-10-30
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-23